Multi-center, Open, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of MG4101 in Hepatocellular Carcinoma After TACE
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2017
At a glance
- Drugs MG 4101 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Green Cross LabCell
- 10 Jun 2017 Biomarkers information updated
- 29 Nov 2016 Status changed from not yet recruiting to recruiting.
- 31 Jul 2016 Status changed from planning to not yet recruiting.